Abstract
The effect of combining RDC-11 (a new ruthenium organometallic complex) and fast neutrons (high-LET radiations) has been evaluated in RDM4 and U-87 tumor cell lines. After co-treatment, a substantial reduction of cell growth was recorded, which appears not to be correlated with the induction of apoptosis.
Keywords: Ruthenium-based anticancer drugs, Apoptosis, High-LET radiation, Concomitant chemoradiotherapy, Fast neutrons
Letters in Drug Design & Discovery
Title: Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture
Volume: 5 Issue: 1
Author(s): P. Bischoff, L. Leyva, F. Malek, S. Benzina, J. M. Denis, J. Gueulette, P. Dufour, C. Gaiddon, J. P. Loeffler, C. Sirlin and M. Pfeffer
Affiliation:
Keywords: Ruthenium-based anticancer drugs, Apoptosis, High-LET radiation, Concomitant chemoradiotherapy, Fast neutrons
Abstract: The effect of combining RDC-11 (a new ruthenium organometallic complex) and fast neutrons (high-LET radiations) has been evaluated in RDM4 and U-87 tumor cell lines. After co-treatment, a substantial reduction of cell growth was recorded, which appears not to be correlated with the induction of apoptosis.
Export Options
About this article
Cite this article as:
Bischoff P., Leyva L., Malek F., Benzina S., Denis M. J., Gueulette J., Dufour P., Gaiddon C., Loeffler P. J., Sirlin C. and Pfeffer M., Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture, Letters in Drug Design & Discovery 2008; 5 (1) . https://dx.doi.org/10.2174/157018008783406714
DOI https://dx.doi.org/10.2174/157018008783406714 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Intraarticular Treatments for Osteoarthritis: New Perspectives
Current Drug Targets Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry Alginate Bead-Encapsulated PEDF Induces Ectopic Bone Formation In Vivo in the Absence of Co-Administered Mesenchymal Stem Cells
Current Drug Targets The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy
Anti-Cancer Agents in Medicinal Chemistry Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Novel Benzo[B]Furans with Anti-Microtubule Activity Upregulate Expression of Apoptotic Genes and Arrest Leukemia Cells in G2/M Phase
Anti-Cancer Agents in Medicinal Chemistry The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Extracellular SH3 Domain Containing Proteins – Features of a New Protein Family
Current Protein & Peptide Science Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design